ArticleFrontiers in oncology2025
Survival nomogram for melanoma with bone metastasis based on the SEER database and an external validation cohort.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to develop and validate a comprehensive prognostic model for melanoma bone metastasis. Methods: Data on melanoma bone metastasis patients were obtained from the SEER database and Fujian Cancer Hospital. Cox regression analysis was conducted to identify independent prognostic factors and to establish a Nomogram to predict the overall survival rate of patients. Results: We generated a Nomogram chart incorporating factors such as Age, Site, AJCC T stage, AJCC N stage, Surg Prim, Systemic and Sur Seq, Surg or Rad Seq, DX Brain, DX Liver, DX Distant LN, Tumor number, First malignant primary, Marital status, and Urban. The 1-year, 3-year, and 5-year OS rate AUCs for the training cohort were 0.715, 0.711, and 0.714, respectively, with a c-index of 0.656; the 1-year, 3-year, and 5-year OS rate AUCs for the internal validation cohort were 0.695, 0.725, and 0.719, respectively, with a c-index of 0.650; the 1-year, 3-year, and 5-year OS rate AUCs for the external validation cohort were 0.714, 0.791, and 0.842, respectively, with a c-index of 0.710. Calibration curves showed the consistency between the Nomogram's observed and predicted prognostic outcomes. Conclusion: Our model can be used to predict the prognosis of melanoma bone metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.